Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia

December 11, 2023

https://www.globenewswire.com/news-release/2023/12/10/2793464/0/en/Centessa-Pharmaceuticals-Announces-New-Data-from-an-Additional-52-Weeks-of-Continuous-Treatment-from-Third-Year-Part-5-of-Ongoing-Phase-2a-Study-of-SerpinPC-for-the-Treatment-of-He.html

BOSTON and LONDON, Dec. 10, 2023 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq:CNTA), today announced new data from an additional 52-weeks of continuous treatment from the third year (Part 5) of the ongoing Phase 2a study of SerpinPC for the treatment of hemophilia. The data were shared in a poster presentation at the American Society of Hematology (ASH) Annual Meeting on Sunday, December 10, 2023. SerpinPC is an investigational subcutaneously administered novel inhibitor of activated protein C (APC) in registrational studies for the treatment for hemophilia B, with or without inhibitors.

Read more at globenewswire.com

Related news for (CNTA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.